Chief Medical Officer · Enliven Therapeutics, Inc. (ELVN)

Kenneth Attie

FY2021 is the first fiscal year CompBrief holds for Kenneth Attie as a named executive officer of Enliven Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$1,621,940

Salary $400,750Stock awards $0Bonus $179,500

2nd of 3 named executive officers at Enliven Therapeutics by FY2021 total.

3 named officers on file for Enliven Therapeutics, FY2021

Kenneth Attie’s pay file — $29

  • 1 fiscal year of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Enliven Therapeutics’s whole pay program stands against its peers

  • Enliven Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ELVN→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 22, 2022 (DEF 14A).

Free

Get Kenneth Attie’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Kenneth Attie compensation by year

Enliven Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Enliven Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021
Salary$400,750
Bonus$179,500
Stock awards$0
Option awards$1,040,600
Non-equity incentive$0
Pension and deferred compensation$0
All other$1,090
Total$1,621,940

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Enliven Therapeutics, Inc. DEF 14A filed April 22, 2022, accession 0001193125-22-114052, and prior-year filings.

How this page was built: the Enliven Therapeutics, Inc. filed document, accession 0001193125-22-114052. Every figure is read from that document and cited to the page and table it appears in. Filed April 22, 2022.

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
Option110,000—$13.83

Per the Outstanding Equity Awards at Fiscal Year-End table in Enliven Therapeutics, Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.

Enliven Therapeutics’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
Rahul BallalPresident and Chief Executive Officer$1,951,029
Kenneth Attie · this pageChief Medical Officer$1,621,940
Michael GrayChief Financial Officer and Chief Operating Officer$1,216,404

The full Enliven Therapeutics compensation record

free company brief

This page is one person within Enliven Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Enliven Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Kenneth Attie's compensation dossier · One-time report. No refunds.